Cas:149003-01-0 dexrazoxane hydrochloride manufacturer & supplier

Chemical Name:dexrazoxane hydrochloride

CAS.NO:149003-01-0

Synonyms:2,6-Piperazinedione, 4-[(1S)-2-(3,5-dioxo-1-piperazinyl)-1-methylethyl]-, hydrochloride (1:1);4,4′-(2S)-Propan-1,2-diyldipiperazin-2,6-dionhydrochlorid;4,4′-(2S)-propane-1,2-diyldipipérazine-2,6-dione chlorhydrate;(S)-4,4′-(1-Methyl-1,2-ethanediyl)bis-2,6-piperazinedionehydrochloride;Dexrazoxane hydrochloride;2,6-Piperazinedione, 4,4′-[(1S)-1-methyl-1,2-ethanediyl]bis-, hydrochloride (1:1);4,4′-[(2S)-1,2-Propanediyl]di(2,6-piperazinedione) hydrochloride (1:1);2,6-piperazinedione, 4,4′-[(1S)-1-methyl-1,2-ethanediyl]bis-, monohydrochloride;4,4′-(2S)-Propane-1,2-diyldipiperazine-2,6-dione hydrochloride (1:1);Dexrazoxane HCl;UNII:5346058Q7S;Dexrazoxane (Hydrochloride)

Molecular Formula:C₁₁H₁₇ClN₄O₄

Molecular Weight:304.73000

HS Code:

Physical and Chemical Properties:

Melting point:193ºC

Boiling point:531.5ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:98.82000

Exact Mass:304.09400

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,6-Piperazinedione, 4-[(1S)-2-(3,5-dioxo-1-piperazinyl)-1-methylethyl]-, hydrochloride (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dexrazoxane (Hydrochloride) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(S)-4,4′-(1-Methyl-1,2-ethanediyl)bis-2,6-piperazinedionehydrochloride Use and application,2,6-Piperazinedione, 4,4′-[(1S)-1-methyl-1,2-ethanediyl]bis-, hydrochloride (1:1) technical grade,usp/ep/jp grade.

Related News: Taiwan complained on Sunday that it was being punished because the World Health Organization considers it part of China, which has been subject to travel bans as the coronavirus spreads. dexrazoxane hydrochloride manufacturer API and raw material are often confused due to the similar usage of the two terms. dexrazoxane hydrochloride supplier One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. dexrazoxane hydrochloride vendor Taiwan complained on Sunday that it was being punished because the World Health Organization considers it part of China, which has been subject to travel bans as the coronavirus spreads. dexrazoxane hydrochloride factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.